Core Points - The article reports that Cai Dongchen, the executive director and chairman of CSPC Pharmaceutical Group (01093.HK), increased his shareholding by purchasing 3 million shares at an average price of HKD 8.81 per share, totaling approximately HKD 26.43 million [1] - Following this transaction, Cai's total shareholding increased to 2,842,118,670 shares, raising his ownership percentage from 24.64% to 24.67% [1] Summary by Sections - **Share Purchase Details** - Cai Dongchen acquired 3 million shares at an average price of HKD 8.81 per share [1] - The total investment for this purchase was about HKD 26.43 million [1] - **Shareholding Changes** - After the purchase, Cai's total shares held reached 2,842,118,670 [1] - His ownership percentage increased from 24.64% to 24.67% [1]

Summary of Conference Call on Corning Jereh & CSPC Pharmaceutical Group ESMO Data Interpretation Company and Industry Overview - The conference call discusses clinical data and future plans for GS-003, a drug developed by Corning Jereh and CSPC Pharmaceutical Group, focusing on its applications in oncology, specifically in platinum-resistant ovarian cancer (PROC), HER2-positive colorectal cancer, and HER2-positive breast cancer. Key Points and Arguments Clinical Efficacy of GS-003 - In PROC, GS-003 demonstrated an objective response rate (ORR) of 32%, a disease control rate (DCR) of 72%, a median progression-free survival (PFS) of 4.1 months, and a 9-month overall survival (OS) rate of 65.4% with a treatment-related adverse event (TRAE) rate of 15.4% [1][2] - In HER2-positive colorectal cancer, GS-003 showed an ORR of 68.8%, a DCR close to 97%, a median PFS of 11.4 months, and a median duration of response (DOR) of 9.9 months, outperforming existing treatments like DS8,201 and TQB2,102 [1][5] - The 026 project for HER2-positive gastric cancer showed significant PFS improvement (HR=0.25) compared to the control group, with a TRAE rate of 60% [1][9][10] Future Development Plans - GS-003 plans to submit a marketing application for HER2-positive breast cancer in 2026 and expects to report phase III clinical data for PROC in 2027 [1][6] - The company aims to explore additional indications and conduct clinical trials for gastric cancer and other cancers, with a focus on both high and low HER2 expression markets [1][7][11] Competitive Landscape - GS-003 is positioned as a best-in-class product in HER2-positive colorectal cancer, with superior efficacy compared to existing therapies [5][11] - The combination of GS-003 and 026 is expected to cover the entire lifecycle management of breast and gastric cancers, enhancing competitive positioning in both high and low HER2 expression markets [1][11] Safety and Tolerability - The safety profile of GS-003 in PROC and colorectal cancer shows a manageable TRAE rate, indicating a favorable risk-benefit ratio compared to other treatments [2][10] - The 026 project reported a higher TRAE rate due to longer chemotherapy cycles, which is considered normal given the treatment duration [10] Market Potential and Strategy - The combination of GS-003 and 026 is anticipated to fill unmet clinical needs in various cancer types, with a strategic focus on leveraging existing data to attract partnerships for overseas clinical development [1][19] - The company plans to utilize combination therapies to enhance treatment efficacy and patient outcomes, particularly in HER2-positive populations [14][19] Insights on Future Trials - The company is considering a segmented market strategy for HER2-positive gastric and breast cancer, aiming to maximize the advantages of both GS-003 and 026 [12][18] - Ongoing clinical trials are exploring various drug combinations for gastric cancer, with promising early results [19] Additional Important Insights - The conference highlighted the potential of dual antibodies and ADCs in improving treatment outcomes for HER2-positive cancers, suggesting a shift in therapeutic strategies [14][21] - The anticipated results from ongoing trials could significantly impact the market positioning of GS-003 and 026, with expectations of long-term survival benefits for patients [21]

Core Viewpoint - The Chinese asset market is experiencing a significant adjustment, with A-shares and Hong Kong stocks declining sharply, particularly in high-tech sectors, while the healthcare sector shows signs of resilience and potential investment opportunities [1][3][4]. A-shares and ETFs Performance - A-shares saw all three major indices decline, with the Shenzhen Component Index and the ChiNext Index both dropping over 3%, while the largest medical ETF (512170) fell by 2.39% but showed strong buying interest with a trading volume increase of 30% to 687 million yuan [1][3]. - The only drug ETF in the market (562050) outperformed the market with a decline of only 1.56%, indicating strong buying momentum as it traded at a premium throughout the day [3]. Hong Kong Stocks and Innovation Drugs - The Hong Kong innovation drug sector has faced volatility, with the Hong Kong Stock Connect Innovation Drug ETF (520880) dropping 2.53% after two consecutive days of gains, while 33 out of 37 covered companies saw declines [3][4]. - Despite the downturn, the Hong Kong innovation drug ETF has also been trading at a premium, with a net inflow of over 128 million yuan in the past five days, suggesting continued investor interest [3][4]. Market Trends and Investment Strategies - The market is shifting from high-tech assets to dividend-paying assets, with healthcare ETFs and innovation drug ETFs attracting significant capital inflows [3][4]. - Analysts predict a potential rebound for the innovation drug sector in the fourth quarter, driven by multiple catalysts such as industry conferences, favorable quarterly earnings, and upcoming national healthcare negotiations [4][5]. Investment Recommendations - Investment strategies focus on identifying companies with strong quarterly earnings, particularly in the CXO sector, and balancing portfolios between innovation drugs and other healthcare segments [4][5]. - The medical ETF (512170) is noted for its high cost-performance ratio, with a current PE valuation of 35.1 times, lower than 60% of the past decade, indicating a favorable entry point for investors [3][4].

Investment Rating - The report maintains a rating of "Buy" for the pharmaceutical and biotechnology sector, specifically recommending companies like Zhaoli Pharmaceutical and Fangsheng Pharmaceutical as undervalued high-dividend Chinese medicine stocks [1]. Core Insights - The report highlights that the Chinese medicine sector is characterized by strong cash flow and low debt ratios, making it capable of high dividend payouts. This sector is less affected by international political dynamics, making it a viable defensive strategy in a volatile market [16][17]. - The report ranks sub-sectors in the following order of preference: innovative drugs > research services > CXO > Chinese medicine > medical devices > pharmacies [10][12]. Summary by Sections 1. Significant Excess Returns in Pharmaceutical Stocks - The A-share pharmaceutical index has shown a year-to-date increase of 18.85%, with a weekly decline of 2.48%. The Chinese medicine sector saw a slight increase of 0.38%, while other sectors like medical services and medical devices experienced declines [4][9]. 2. High Dividend Yield in Chinese Medicine Sector - The report emphasizes the attractiveness of high dividend yields in the Chinese medicine sector, with companies like Zhaoli Pharmaceutical expected to have a dividend yield of 4.1% in 2025, and Fangsheng Pharmaceutical at 3.1% [17][18]. 3. R&D Progress and Company Dynamics - Recent developments include the approval of innovative drugs and clinical trials by various companies, indicating ongoing advancements in the sector [4][12]. 4. Industry and Regulatory Insights - The report provides insights into the regulatory landscape affecting the pharmaceutical industry, noting that the impact of tariff wars on the sector is limited [4]. 5. Market Review - The report tracks the performance of various pharmaceutical sub-sectors, noting that the Chinese medicine sector has outperformed others in recent weeks [4][9].

Investment Rating - The report maintains an investment rating of "Outperform" for the biopharmaceutical sector [8]. Core Insights - The report highlights several catalysts for the sector, including academic conferences, business development (BD) achievements, medical insurance negotiations, and innovative drug directories from commercial insurance [21]. - Key companies to watch include: 1. Products with high certainty for overseas expansion certified by MNCs: PD-1 upgraded products from Sanofi and GLP-1 assets from Federal Pharmaceuticals [21]. 2. Potential blockbuster products for overseas licensing from MNCs: PD-1 upgraded products from Kangfang Biotech and Innovent Biologics, breakthroughs in autoimmune fields from Yifang Biotech and China Antibody, and innovative target ADCs from Fuhong Hanlin and Shiyao Group [21]. 3. Companies likely to benefit from medical insurance negotiations and innovative drug directories: Heng Rui Medicine, Kangnuo Pharmaceutical, Maiwei Biotech, Zhixiang Jintai, and Haichuang Pharmaceutical [21]. Summary by Sections Weekly New Drug Market Review - From October 13 to October 19, 2025, the top five gainers in the new drug sector were: - Sanofi National Health (+12.68%) - Kangning Jereh (+10.18%) - Rongchang Biotech (+5.42%) - Xiansheng Pharmaceuticals (+4.88%) - Qianyan Biotech (+3.77%) - The top five losers were: - Yongtai Biotech (-29.76%) - Betta Pharmaceuticals (-16.98%) - Yiming Oncology (-16.80%) - Deqi Pharmaceuticals (-15.30%) - WuXi Biologics (-13.43%) [4][16]. New Drug Industry Focus Analysis - Recently, Bai Li Tianheng presented overseas multi-center solid tumor research data for its EGFR×HER3 dual antibody ADC drug, iza-bren, at the 2025 European Society for Medical Oncology (ESMO) annual meeting. The data showed consistent efficacy and safety across different populations, confirming the broad-spectrum tumor-killing efficacy of iza-bren [21][24]. New Drug Approval and Acceptance - This week, one new drug or new indication application was approved, and 13 new drug or new indication applications were accepted in China [9][27]. - Additionally, 30 new drug clinical applications were approved, and 47 new drug clinical applications were accepted [10][30].

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) announced the interim analysis results of the KN026 combined chemotherapy for HER2+ GC (including GEJ) in a Phase III clinical trial, showing significant clinical benefits compared to the control group [1][2]. Group 1: Clinical Trial Results - The interim analysis demonstrated that KN026 combined chemotherapy achieved clinically meaningful and statistically significant benefits in progression-free survival (PFS) and overall survival (OS) compared to the placebo group [2]. - The median follow-up time for the Anlotinib group was 9.7 months, while the control group had a median follow-up of 9.8 months [2]. Group 2: Patient Characteristics - The baseline characteristics of patients in both groups were generally balanced, with a median age of approximately 64 years in the Anlotinib group and 61 years in the control group [1]. - Over 80% of patients in both groups had an ECOG PS score of 1, and nearly all patients were diagnosed with stage IVB disease at enrollment [1]. Group 3: Mechanism of Action - KN026 aims to be a next-generation HER2-targeted therapy, capable of dual binding to two clinically validated HER2 epitopes (epitopes II and IV) while retaining the wild-type Fc region [2]. - This mechanism allows KN026 to dual-block HER2-related signaling pathways, enhance binding to HER2 receptors, reduce surface HER2 protein, and improve tumor-killing effects through complete antibody-dependent cellular cytotoxicity [2]. Group 4: Ongoing Clinical Trials - Multiple Phase III clinical trials are currently underway in China, including KN026 combined with docetaxel for first-line treatment of HER2+ breast cancer, and KN026 combined chemotherapy for second-line and above treatment of HER2+ GC/GEJ [3].

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) announced the interim analysis results of the KN026 combined chemotherapy for HER2+GC (including GEJ) in a Phase III clinical trial, indicating significant clinical benefits in progression-free survival (PFS) and overall survival (OS) compared to the control group [1][2]. Group 1: Clinical Trial Results - The interim analysis presented at the 2025 ESMO conference showed that KN026 combined with chemotherapy demonstrated clinically meaningful and statistically significant benefits in PFS and OS compared to the placebo group [2]. - The median follow-up time for the Anlotinib group was 9.7 months, while the control group had a median follow-up of 9.8 months [2]. Group 2: Patient Characteristics - The baseline characteristics of patients in both groups were generally balanced, with a median age of approximately 64 years in the Anlotinib group and 61 years in the control group [1]. - Over 80% of patients in both groups had an ECOG PS score of 1, and nearly all patients were diagnosed with stage IVB disease at enrollment [1]. Group 3: Mechanism of Action - KN026 aims to be a next-generation HER2-targeted therapy, capable of dual binding to two clinically validated HER2 epitopes (epitopes II and IV) while retaining the wild-type Fc region [2]. - This mechanism allows KN026 to dual-block HER2-related signaling pathways, enhance binding to HER2 receptors, reduce surface HER2 protein, and improve tumor-killing effects through complete antibody-dependent cellular cytotoxicity [2]. Group 4: Ongoing Clinical Trials - Multiple Phase III clinical trials are currently underway in China, including KN026 combined with docetaxel for first-line treatment of HER2+BC, KN026 combined chemotherapy for second-line and above treatment of HER2+GC/GEJ, and KN026 combined with docetaxel for neoadjuvant treatment of BC [3].

Core Viewpoint - The Chinese asset market is undergoing a significant adjustment, with major indices in A-shares and Hong Kong experiencing sharp declines, particularly in high-tech stocks, while the healthcare sector shows signs of strong buying interest despite the overall market downturn [1][3][7]. A-Shares Market - A-shares saw all three major indices decline, with the Shenzhen Component Index and the ChiNext Index both dropping over 3% [1]. - The largest medical ETF in A-shares (512170) focused on medical devices and CXO, closed down 2.39% but experienced a significant increase in trading volume, with a 30% rise to 687 million yuan, indicating strong buying pressure [1][5]. - The medical sector has been on a downward trend for several years, but this year has shown significant recovery, with current price and valuation levels still at historical lows, suggesting a high margin of safety [5]. Hong Kong Market - The Hong Kong innovative drug sector has experienced high volatility, with the Hong Kong Stock Connect Innovative Drug ETF (520880) dropping 2.53% and seeing a decrease in trading volume to 313 million yuan [3]. - Among the 37 companies covered by the ETF, 33 saw declines, with major stocks like China Biologic Products, CSPC Pharmaceutical Group, and CanSino Biologics all falling over 4% [3]. - The innovative drug sector in Hong Kong has faced a correction after a significant surge earlier in the year, with profit-taking observed since mid-September [7]. Investment Strategies - Analysts suggest that the innovative drug sector may be entering a configuration window, with multiple catalysts expected in the fourth quarter, including industry conferences and positive earnings forecasts [7]. - Investment strategies focus on identifying companies with strong third-quarter earnings and exploring opportunities in the innovative drug sector, while also considering underperforming segments like medical devices and services [7][8]. ETF Performance - The medical ETF (512170) and the Hong Kong Stock Connect Innovative Drug ETF (520880) have attracted significant capital inflows recently, indicating a shift in market sentiment towards these sectors [8]. - The medical ETF is the largest in the market, with a scale of 26.4 billion yuan, and is noted for its unique focus on the pharmaceutical sector [10].

Group 1 - The chairman and executive director of the company, Cai Dongchen, increased his stake in the company by purchasing 3 million shares at a price of HKD 8.81 per share, totaling HKD 26.43 million [1] - Following the purchase, the total number of shares held by Cai Dongchen is approximately 2.842 billion, representing a holding percentage of 24.67% [1]

Group 1 - The chairman and executive director of the company, Cai Dongchen, increased his stake in the company by purchasing 3 million shares at a price of HKD 8.81 per share, totaling HKD 26.43 million [1] - Following the purchase, the total number of shares held by Cai Dongchen is approximately 2.842 billion, representing a holding percentage of 24.67% [1]